Aurobindo Pharma reported a 25% year-on-year increase in net profit to ₹1,032 crore for the first quarter ended June 30, 2026.
The Hyderabad-based generic drugmaker also posted a record revenue of ₹9,150 crore, up from ₹824 crore in net profit during the same period last year.
5% after reporting a sharp acceleration in first-quarter fiscal 2027 profitability.
The results highlight broad-based growth across the company's business lines, according to Hindu Businessline.
The strong performance comes as Indian pharmaceutical companies navigate a complex global regulatory environment while benefiting from robust demand in key export markets.
Aurobindo's results align with a positive trend among Indian healthcare and pharma peers.
Earlier in the week, Dr Agarwal's Health Care saw shares rise 5.5% after reporting a sharp acceleration in first-quarter fiscal 2027 profitability.